US-based biotechnology company BioMarin Pharmaceutical has announced the completion of an underwritten public offering of senior subordinated convertible notes to raise $450m.
The notes carry a rate of 0.599% and are due on 1 August 2024.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
BioMarin plans to use the funds to repay debt, repurchase notes due in October 2018, as well as for general corporate purposes.
Spectrum Pharmaceuticals plans for a private placement of shares to raise up to $150m.
The US-based biopharmaceutical company plans to use the funds towards general corporate purposes.
Chinese pharmaceutical company Orient Pharma plans to issue 21 million common stock shares priced at NT$20 ($D0.6) each to raise NT$425m ($14.06m).
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe company plans to use the funds towards loan repayment and for working capital purposes.
